Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.

Clinical pharmacology and therapeutics - 1 Dec 1993

LLerena A, Herraíz A G, Cobaleda J, Johansson I, Dahl M L

Abstract excerpt

Debrisoquin and S-mephenytoin hydroxylation phenotypes were determined in 72 Spanish psychiatric patients treated with neuroleptic or antidepressant agents. One patient (1.4%) was classified as a poor metabolizer of S-mephenytoin. Between both neuroleptic- and antidepressant-treated patients, the distribution of the debrisoquin metabolic ratio was shifted toward higher values compared with 54 drug-free healthy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 Enzyme System

Share to Debrisoquin

Share to Genotype

Share to Mixed Function Oxygenases

Share to Phenotype

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 7903915
DOI: 10.1038/clpt.1993.197

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.PMID 7903915Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.Semantic proximity Read ↗

Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians.Semantic proximity Read ↗

Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.Semantic proximity Read ↗

[CYP2D6 gene polymorphism in psychiatric patients resistant to standard pharmacotherapy].Semantic proximity Read ↗

Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.Semantic proximity Read ↗

Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.Semantic proximity Read ↗

Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia.Semantic proximity Read ↗

Genetically determined adverse drug reactions involving metabolism.Semantic proximity Read ↗

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.Semantic proximity Read ↗

Pharmacogenetics of antidepressants: clinical aspects.Semantic proximity Read ↗

Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.